A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
A phase 2 trial of Atezolizumab in small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07654400 by Sichuan Baili Pharmaceutical Co., Ltd., with 36 participants planned, started 2026-07-09 and due to reach its primary completion in 2027-12. Interventions recorded: BL-M14D1, Atezolizumab. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
- TrialBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Shares SystImmune / Sichuan Biokin, Atezolizumab, Small-cell lung cancer.
- TrialA Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Shares Atezolizumab, Small-cell lung cancer.
- TrialA Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Shares Atezolizumab, Small-cell lung cancer.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Atezolizumab, Small-cell lung cancer.
- TrialA Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
- TrialA Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer